NCT06256315

Brief Summary

This clinical trial aims to explore the safety and effectiveness of the Hyper-ERAS rehabilitation protocol for colorectal cancer patients and the feasibility of discharge within 48 hours.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
160

participants targeted

Target at P25-P50 for not_applicable colorectal-cancer

Timeline
Completed

Started Jun 2023

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2023

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

February 5, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 13, 2024

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2025

Completed
Last Updated

February 13, 2024

Status Verified

February 1, 2024

Enrollment Period

2 years

First QC Date

February 5, 2024

Last Update Submit

February 12, 2024

Conditions

Keywords

Colorectal CancerHyper-ERASSuper Accelerated Rehabilitation SurgeryRapid RehabilitationPerioperative ManagementERAS2.0

Outcome Measures

Primary Outcomes (1)

  • 30-day overall complication rate

    The primary endpoint was the 30-day overall complication rate.

    30 days after surgery

Secondary Outcomes (2)

  • Severe complications (CD≥IIIb) rate, within 30 days after surgery

    30 days after surgery

  • The rehospitalization rate within 30 days after surgery

    30 days after surgery

Study Arms (3)

Group A:Hyper-ERAS(Length of Postoperative Hospital Stay<48h)

EXPERIMENTAL

Patients treated with the Hyper-ERAS rehabilitation protocol and discharged within 48 hours were in group A.

Procedure: Hyper-ERAS Program

Group B:Hyper-ERAS(LOPS>48h)

EXPERIMENTAL

Patients treated with the ERAS rehabilitation protocol and discharged in more than 48 hours were in group B.

Procedure: Hyper-ERAS Program

Group C:Control group

NO INTERVENTION

Patients eligible but not treated with the Hyper-ERAS rehabilitation protocol during the same period were in group C.

Interventions

Patients who met the inclusion criteria were treated with Hype-ERAS protocol, including preoperative education, intraoperative quality control, postoperative preventive analgesia, early ambulation, early recovery of diet, early removal of the drainage tube, urinary catheter, and gastric tube, and discharge within 48 hours or more than 48 hours safter surgery, and closely and standardized follow-up outside the hospital.

Group A:Hyper-ERAS(Length of Postoperative Hospital Stay<48h)Group B:Hyper-ERAS(LOPS>48h)

Eligibility Criteria

Age18 Years - 79 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Pathologically confirmed colorectal cancer.
  • The position of the anastomosis is above the peritoneal reflection.
  • Age range from 18 to 79 years old.
  • No surgical contraindications.
  • The patient has good compliance and can understand the concept of rapid recovery.
  • Possess basic nursing conditions outside the hospital, and can arrive at the hospital within 30 minutes after discharge.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking University Cancer Hospital & Institute

Beijing, Haidian District, 100142, China

RECRUITING

MeSH Terms

Conditions

Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Unit III & Ostomy Service, Gastrointestinal Cancer Center

Study Record Dates

First Submitted

February 5, 2024

First Posted

February 13, 2024

Study Start

June 1, 2023

Primary Completion

June 1, 2025

Study Completion

August 1, 2025

Last Updated

February 13, 2024

Record last verified: 2024-02

Locations